Falcon's Beyond Appoints New Board Member
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy FBYD?
Source: Newsfilter
- New Board Member: Falcon's Beyond has appointed Iraida Que De Vera to its Board of Directors; as the Founder and CEO of Amor Maximus, her focus on real estate and capital stewardship is expected to bring valuable industry experience and strategic insights to the company.
- Global Market Experience: Iraida has a successful background as a real estate broker in various international markets, including Las Vegas, Vancouver, and Milan, and her cross-border expansion expertise will aid Falcon's Beyond in its global business growth and market penetration.
- CEO's Praise: Cecil D. Magpuri, CEO of Falcon's Beyond, stated that Iraida's real estate insights and global development expertise will add significant value to the board, supporting the company's innovation in immersive experiences.
- Support for Company Vision: Iraida expressed her honor in joining the board at a pivotal moment for the company and looks forward to supporting Falcon's Beyond's bold vision, driving growth in high-potential business areas such as content, technology, and experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBYD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBYD
About FBYD
Falcon’s Beyond Global, Inc. is engaged in innovative and immersive storytelling. The Company propels intellectual property (IP) activations across physical and digital experiences through three core business units: Falcon’s Creative Group (FCG), Falcon’s Beyond Destinations (FBD), and Falcon’s Beyond Brands (FBB). FCG creates master plans, designs attractions and experiential entertainment, and produces content, interactives and software. FBD develops a diverse range of entertainment experiences using both owned and third-party licensed intellectual property, consisting of Producciones de Parques, S.L. (PDP), and Destinations Operations, which develops a diverse range of entertainment experiences using both Company owned, and third-party licensed intellectual property, spanning location-based entertainment, dining, and retail. FBB brings brands and intellectual property to life through animation, movies, licensing and merchandising, gaming, as well as ride and technology sales.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Falcon’s Beyond Appoints Iraida Que De Vera to Board of Directors
- New Board Member: Falcon’s Beyond has appointed Iraida Que De Vera to its Board of Directors; she is the Founder and CEO of Amor Maximus, focusing on real estate and capital stewardship, which is expected to bring valuable industry experience to the company.
- Global Perspective: Iraida Que De Vera has a successful background as a real estate broker in multiple international markets, including Las Vegas, Vancouver, and Milan, and her cross-border expansion experience will aid Falcon’s Beyond in its strategic positioning in global markets.
- Strategic Value: Falcon’s Beyond CEO Cecil D. Magpuri stated that Iraida’s real estate insights and global development expertise will provide crucial support for the company, enhancing its innovation in immersive experiences.
- Company Vision: Iraida expressed her eagerness to support Falcon’s Beyond’s bold vision, contributing to the company’s ongoing success in creating value for families and communities, highlighting the company’s potential in the immersive experience market.
See More
Falcon's Beyond Appoints New Board Member
- New Board Member: Falcon's Beyond has appointed Iraida Que De Vera to its Board of Directors; as the Founder and CEO of Amor Maximus, her focus on real estate and capital stewardship is expected to bring valuable industry experience and strategic insights to the company.
- Global Market Experience: Iraida has a successful background as a real estate broker in various international markets, including Las Vegas, Vancouver, and Milan, and her cross-border expansion expertise will aid Falcon's Beyond in its global business growth and market penetration.
- CEO's Praise: Cecil D. Magpuri, CEO of Falcon's Beyond, stated that Iraida's real estate insights and global development expertise will add significant value to the board, supporting the company's innovation in immersive experiences.
- Support for Company Vision: Iraida expressed her honor in joining the board at a pivotal moment for the company and looks forward to supporting Falcon's Beyond's bold vision, driving growth in high-potential business areas such as content, technology, and experiences.
See More
Falcon's Beyond (FBYD) Stock Rallies 15% Amid Ongoing Liquidity Concerns
- Stock Rebound: Falcon's Beyond's stock surged 15% on Friday, closing at $6.96, despite a prior streak of 11 consecutive down days, indicating cautious optimism from the market regarding its future prospects.
- Long-term Decline: Even with Friday's rebound, FBYD has fallen 59% since its close on December 29, reflecting ongoing liquidity challenges and a lack of market confidence in the company.
- Financial Management Concerns: Analyst Bashar Issa highlighted that Falcon's Beyond's poor financial management could lead to disappointing investment returns, although he noted potential surprises from the Creative Group as Qiddiya theme park projects progress.
- Cautious Investment Advice: Issa advises investors to watch FBYD but not rush to buy, indicating a cautious market sentiment regarding the company's future performance, especially with unresolved liquidity issues.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
See More
Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 100 points on Monday.
Kyverna Therapeutics Surge: Kyverna Therapeutics Inc. shares rose 31% to $11.49 following the announcement of positive topline data from its Phase 2 trial of mivocabtagene autoleucel for stiff person syndrome.
Other Notable Stock Gains: Beneficient, Immunome Inc., and Falcon’s Beyond Global recorded significant gains, with increases of 29.3%, 25.5%, and 14% respectively.
Additional Stock Movements: Several other companies, including Almonty Industries and NovaBay Pharmaceuticals, also saw notable increases in their stock prices, contributing to a generally positive day for select stocks despite the overall market decline.
See More
Falcon’s Beyond Appoints Iraida Que De Vera to Board of Directors
- New Board Member: Falcon’s Beyond has appointed Iraida Que De Vera to its Board of Directors; she is the Founder and CEO of Amor Maximus, focusing on real estate and capital stewardship, which is expected to bring valuable industry experience to the company.
- Global Perspective: Iraida Que De Vera has a successful background as a real estate broker in multiple international markets, including Las Vegas, Vancouver, and Milan, and her cross-border expansion experience will aid Falcon’s Beyond in its strategic positioning in global markets.
- Strategic Value: Falcon’s Beyond CEO Cecil D. Magpuri stated that Iraida’s real estate insights and global development expertise will provide crucial support for the company, enhancing its innovation in immersive experiences.
- Company Vision: Iraida expressed her eagerness to support Falcon’s Beyond’s bold vision, contributing to the company’s ongoing success in creating value for families and communities, highlighting the company’s potential in the immersive experience market.
See More
Falcon's Beyond Appoints New Board Member
- New Board Member: Falcon's Beyond has appointed Iraida Que De Vera to its Board of Directors; as the Founder and CEO of Amor Maximus, her focus on real estate and capital stewardship is expected to bring valuable industry experience and strategic insights to the company.
- Global Market Experience: Iraida has a successful background as a real estate broker in various international markets, including Las Vegas, Vancouver, and Milan, and her cross-border expansion expertise will aid Falcon's Beyond in its global business growth and market penetration.
- CEO's Praise: Cecil D. Magpuri, CEO of Falcon's Beyond, stated that Iraida's real estate insights and global development expertise will add significant value to the board, supporting the company's innovation in immersive experiences.
- Support for Company Vision: Iraida expressed her honor in joining the board at a pivotal moment for the company and looks forward to supporting Falcon's Beyond's bold vision, driving growth in high-potential business areas such as content, technology, and experiences.
See More
Falcon's Beyond (FBYD) Stock Rallies 15% Amid Ongoing Liquidity Concerns
- Stock Rebound: Falcon's Beyond's stock surged 15% on Friday, closing at $6.96, despite a prior streak of 11 consecutive down days, indicating cautious optimism from the market regarding its future prospects.
- Long-term Decline: Even with Friday's rebound, FBYD has fallen 59% since its close on December 29, reflecting ongoing liquidity challenges and a lack of market confidence in the company.
- Financial Management Concerns: Analyst Bashar Issa highlighted that Falcon's Beyond's poor financial management could lead to disappointing investment returns, although he noted potential surprises from the Creative Group as Qiddiya theme park projects progress.
- Cautious Investment Advice: Issa advises investors to watch FBYD but not rush to buy, indicating a cautious market sentiment regarding the company's future performance, especially with unresolved liquidity issues.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
See More
Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 100 points on Monday.
Kyverna Therapeutics Surge: Kyverna Therapeutics Inc. shares rose 31% to $11.49 following the announcement of positive topline data from its Phase 2 trial of mivocabtagene autoleucel for stiff person syndrome.
Other Notable Stock Gains: Beneficient, Immunome Inc., and Falcon’s Beyond Global recorded significant gains, with increases of 29.3%, 25.5%, and 14% respectively.
Additional Stock Movements: Several other companies, including Almonty Industries and NovaBay Pharmaceuticals, also saw notable increases in their stock prices, contributing to a generally positive day for select stocks despite the overall market decline.
See More
